The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?

Bing Z. Carter, Duncan H. Mak, Jorge Cortes, Michael Andreeff

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating from and ultimately sustained by a rare population of BCR-ABL+ cells with multilineage stem cell properties. Imatinib, the most successful of molecular targeted therapies, has revolutionized treatment of patients with CML. Despite this achievement, CML is often not curable, largely due to the innate insensitivity of CML stem cells, particularly when in a quiescent state. This failure of not only imatinib but also the second-generation tyrosine kinase inhibitors (TKIs) frequently leads to relapse upon drug discontinuation. Thus, any curative therapy must eliminate CML stem cells. A comprehensive understanding of the biological properties of CML stem cells and an elucidation of the molecular mechanisms and signaling pathways enabling these CML stem cells to self-renew, combined with insight into the regulation of apoptosis signaling and the mechanisms governing the interaction of CML stem cells with their bone marrow microenvironment, will facilitate the development of therapies for targeting these cells. Here, we discuss the biological properties of CML stem cells and potential strategies to eliminate them.

Original languageEnglish (US)
Pages (from-to)362-370
Number of pages9
JournalSeminars in Hematology
Volume47
Issue number4
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Myeloid Progenitor Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Targeted Therapy
Cell- and Tissue-Based Therapy
Protein-Tyrosine Kinases
Stem Cells
Bone Marrow
Apoptosis
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

The Elusive Chronic Myeloid Leukemia Stem Cell : Does It Matter and How Do We Eliminate It? / Carter, Bing Z.; Mak, Duncan H.; Cortes, Jorge; Andreeff, Michael.

In: Seminars in Hematology, Vol. 47, No. 4, 01.10.2010, p. 362-370.

Research output: Contribution to journalArticle

Carter, Bing Z. ; Mak, Duncan H. ; Cortes, Jorge ; Andreeff, Michael. / The Elusive Chronic Myeloid Leukemia Stem Cell : Does It Matter and How Do We Eliminate It?. In: Seminars in Hematology. 2010 ; Vol. 47, No. 4. pp. 362-370.
@article{f6f94dcc515247879776b342b67dbf0f,
title = "The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?",
abstract = "Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating from and ultimately sustained by a rare population of BCR-ABL+ cells with multilineage stem cell properties. Imatinib, the most successful of molecular targeted therapies, has revolutionized treatment of patients with CML. Despite this achievement, CML is often not curable, largely due to the innate insensitivity of CML stem cells, particularly when in a quiescent state. This failure of not only imatinib but also the second-generation tyrosine kinase inhibitors (TKIs) frequently leads to relapse upon drug discontinuation. Thus, any curative therapy must eliminate CML stem cells. A comprehensive understanding of the biological properties of CML stem cells and an elucidation of the molecular mechanisms and signaling pathways enabling these CML stem cells to self-renew, combined with insight into the regulation of apoptosis signaling and the mechanisms governing the interaction of CML stem cells with their bone marrow microenvironment, will facilitate the development of therapies for targeting these cells. Here, we discuss the biological properties of CML stem cells and potential strategies to eliminate them.",
author = "Carter, {Bing Z.} and Mak, {Duncan H.} and Jorge Cortes and Michael Andreeff",
year = "2010",
month = "10",
day = "1",
doi = "10.1053/j.seminhematol.2010.06.006",
language = "English (US)",
volume = "47",
pages = "362--370",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Elusive Chronic Myeloid Leukemia Stem Cell

T2 - Does It Matter and How Do We Eliminate It?

AU - Carter, Bing Z.

AU - Mak, Duncan H.

AU - Cortes, Jorge

AU - Andreeff, Michael

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating from and ultimately sustained by a rare population of BCR-ABL+ cells with multilineage stem cell properties. Imatinib, the most successful of molecular targeted therapies, has revolutionized treatment of patients with CML. Despite this achievement, CML is often not curable, largely due to the innate insensitivity of CML stem cells, particularly when in a quiescent state. This failure of not only imatinib but also the second-generation tyrosine kinase inhibitors (TKIs) frequently leads to relapse upon drug discontinuation. Thus, any curative therapy must eliminate CML stem cells. A comprehensive understanding of the biological properties of CML stem cells and an elucidation of the molecular mechanisms and signaling pathways enabling these CML stem cells to self-renew, combined with insight into the regulation of apoptosis signaling and the mechanisms governing the interaction of CML stem cells with their bone marrow microenvironment, will facilitate the development of therapies for targeting these cells. Here, we discuss the biological properties of CML stem cells and potential strategies to eliminate them.

AB - Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating from and ultimately sustained by a rare population of BCR-ABL+ cells with multilineage stem cell properties. Imatinib, the most successful of molecular targeted therapies, has revolutionized treatment of patients with CML. Despite this achievement, CML is often not curable, largely due to the innate insensitivity of CML stem cells, particularly when in a quiescent state. This failure of not only imatinib but also the second-generation tyrosine kinase inhibitors (TKIs) frequently leads to relapse upon drug discontinuation. Thus, any curative therapy must eliminate CML stem cells. A comprehensive understanding of the biological properties of CML stem cells and an elucidation of the molecular mechanisms and signaling pathways enabling these CML stem cells to self-renew, combined with insight into the regulation of apoptosis signaling and the mechanisms governing the interaction of CML stem cells with their bone marrow microenvironment, will facilitate the development of therapies for targeting these cells. Here, we discuss the biological properties of CML stem cells and potential strategies to eliminate them.

UR - http://www.scopus.com/inward/record.url?scp=77957090390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957090390&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2010.06.006

DO - 10.1053/j.seminhematol.2010.06.006

M3 - Article

C2 - 20875553

AN - SCOPUS:77957090390

VL - 47

SP - 362

EP - 370

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4

ER -